Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PBAX PHOENIX BIOTECH ACQUISITION CORP
10.5200.0000.00%
Trading Session
02/01 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
10.520
Volume
0.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Sees Large Decrease in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 9,10
Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'
RNA biotech TransCode Therapeutics Inc (NASDAQ:RNAZ) withdrew its S-1 filing with the SEC that it made in late November. TransCode said that the withdrawal reflects TransCode's belief that "current ma
PBAX CEO: Mutually Determined That This Action Is in Best Interest of All Parties Given Current Market Conditions
Intrinsic Medicine, Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Sees Large Increase in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling
Human Milk Drug Developer Intrinsic Medicine to Merge With SPAC Phoenix Biotech
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) Shares Acquired by Wolverine Asset Management LLC
Wolverine Asset Management LLC lifted its position in shares of Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU – Get Rating) by 126.6% in the 2nd quarter, according to its most recent filing with t
Phoenix Biotech to Take Intrinsic Medicine Public in SPAC Deal
11:39 AM EDT, 10/31/2022 (MT Newswires) -- Phoenix Biotech Acquisition (PBAX), a blank-check company, and Intrinsic Medicine said Monday they have agreed to merge in a deal that would take Intrinsic p
Intrinsic Medicine, Phoenix Biotech Acquisition Enter Merger Agreement
Company Overview
More
Phoenix Biotech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 7, 2021 and is headquartered in Oakland, CA.
CEO： Mr. Chris Ehrlich
Market： NASDAQ
Listing Date： 11/30/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet